DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Litton JK, Blum JL, Eiermann W et al.
A phase 3, open-label, randomized, parallel, 2-arm multi-center study of the oral PARP inhibitor BMN 673 versus physicianʼs choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA study). San Antonio Breast Cancer Symposium 2014; Abstract No. OT1-1 – 12.
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.